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Abstract
We describe a high throughput gene expression platform based on microfluidic dynamic arrays. This system allows 2,304
simultaneous real time PCR gene expression measurements in a single chip, while requiring less pipetting than is required
to set up a 96 well plate. We show that one can measure the expression of 45 different genes in 18 tissues with replicates in
a single chip. The data have excellent concordance with conventional real time PCR and the microfluidic dynamic arrays
show better reproducibility than commercial DNA microarrays.
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Introduction
Large scale gene expression analysis has become an essential
tool for many biological and medical investigations. DNA
microarrays are extremely powerful tools for such studies in that
they allow one to probe virtually the entire transcriptome to give
an overall picture of gene expression behavior [1]. However, their
results for any given gene are often noisy or ambiguous [2].
Therefore it has become common practice to check the results of a
genome-wide study with real time PCR (RT-qPCR), which has
excellent sensitivity, dynamic range, and reproducibility and is
widely regarded as the ‘‘gold standard’’ measurement. Unfortu-
nately RT-qPCR is a low throughput technique, which limits the
number genes that can be verified. Furthermore, many microarray
studies are concluded by identifying a set of 20–100 genes which
are the most important determinants of the phenomenon of
interest [3]. Validation studies or practical medical application
then require measurement of those genes on much larger sample
sets than are practical with conventional microarrays. It is
therefore of great interest to create new automation tools that
increase the parallelism and throughput of RT-qPCR.
Microfluidic technology has found a number of applications in
biological automation [4]. The ability to make arbitrary fluidic
manipulations at the nanoliter scale has led to the development of a
number of new tools with applications including protein crystalliza-
tion [5], single cell gene expression [6], and cell culture [7]. It has
been shown that one particularly useful way to apply such small
plumbing is in the creation of microfluidic matrixes, or ‘‘dynamic
arrays’’, that let one perform all possible combinatorial assays on a
set of reagents while realizing significant economies of scale in both
pipetting, labor and reagent consumption [8]. Here we show that
microfluidicdynamicarrayscan beused to performhigh throughput
gene expression measurements with real time PCR. Single chips
were used to measure the expression of 45 genes in 18 different adult
and fetal tissues, and the results were compared both with
microarray measurements and with conventional RT-qPCR.
Results and Discussion
Chip Design and Raw Data
Figure 1A shows a picture of the microfluidic chip used in this
study, a 48.48 dynamic array. The chip is mounted on a plastic
carrier with interface and containment accumulators and 48
sample inlets and detector inlets. The dimensions of the inlets and
the size of the plate conform to SBS standards [9] and are
robotically compatible. The integrated fluidic circuit (IFC) is a
network of fluid lines, NanoFlex
TM valves and chambers. The
NanoFlex
TM valves are made of an elastomeric material which
deflects under pressure to create a tight seal and are used to
regulate the flow of liquids in the IFC. Prior to loading, the chip is
primed using the NanoFlex
TM IFC controller which pressurizes
the control lines and closes the interface valves. Individual samples
are pipetted into the sample inlets and the gene expression assays
are pipetted into the detector inlets. The chip is then placed back
on the NanoFlex
TM IFC controller for loading and mixing. During
this process, pressure is applied to the fluid in the sample inlets and
the fluid is pushed into the fluid lines and then into the individual
wells. At the same time the fluid in the detector inlets is pushed
into the fluid lines. Mixing of the two fluids is prevented by the
closed interface valve. The containment valves are then closed and
the interface valves opened which pushes the reagents in the
detector inlets into the individual reaction chambers to allow for
mixing. At the end of the mixing the interface valves are again
closed and the chip is ready for cycling. This process takes
approximately 55 minutes. While some details of this chip and
process have been previously described [10,11], more details on
the design, function and characterization of the dynamic array
chip are in preparation (Unger M, et al. The Dynamic Array:
High Throughput Real-Time Quantitative PCR by Microfluidic
Large Scale Integration, manuscript in preparation, 2008).
After loading and mixing is complete, the chip is placed into the
instrument for thermal cycling. Once the cycling program has
started, the chip is imaged at the end of each cycle. When the
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eachofthe2304 wells.Figure1Bshows a computer generatedimage
of the data obtained from one of the chips used for the gene
expression analysis study. Forty-five gene expression assays and
preamplified cDNA from 18 different tissues and 3 control
preamplified cDNAs were included in this study. A complete list of
the gene expression assays and cDNAsamples canbefound inTable
S1. Each square of the image represents one of the 2304 wells on the
chip. The different colors indicate different CT values according to
the color key shown on the right side of the figure. Squares that are
black indicate that the CT is greater than 40. For the 48.48 dynamic
array chip used here amplification curves are visible over 6 logs from
aC T value of 7.9 to 25.7 for a gene expression assay with an
efficiency of 89% (Fig. S1, Table S2, supplemental data), which
shows data across a 10-fold serial dilution across 288 replicates of the
same gene. The quality of data is very high; for example, for the
highest concentration (Curve set 1, relative concentration 1610
0),
themeanCtvaluewas7.9,andthestandarddeviationacrossthe288
Cts wasonly0.089.Thisisextremelyhigh quality data. Weroutinely
test our chips by using a similar concentration of sample across the
entire chip (2304 replicates), and typically obtain a standard
deviation of about 0.1 across 2304 replicates (data not shown).The
last curve has a CT of 25.7; the mean copy number for that sample
was measured by microfluidic digital PCR and found to be 8.
Validation of Gene Expression Data
We compared a subset of the gene expression data obtained here
to both microarray data reported for the same tissues and genes and
to conventional real time PCR on microliter volume samples.
GeneNote is a publicly available data set of gene expression in
normal human tissues [12]. The data can be viewed at http://
bioinfo2.weizmann.ac.il/cgi-bin/genenote/home_page.pl . Data for
8ofthe18tissuesusedinthegeneexpressionstudywerefoundinthe
GeneNote data base. These were brain, heart, kidney, liver, lung,
prostate, muscle and spleen. Data for all but MYH1 was found in
GeneNote. For each gene the data from two duplicates is reported.
The plots shown in Fig 2 A,B, C and D represent comparison
data between and within measurement platforms for two tissues
and 43 genes. Fig. 2A shows that the microarray data has
moderate internal consistency, with a correlation coefficient
between replicates of r=0.933 and a number of significant outlier
data points. In Fig. 2B the mean of the two microarray duplicates
is compared to the data from the microfluidic dynamic array
obtained with preamplified cDNA (PA cDNA). For these genes
and tissues the correlation coefficient is only 0.864, a value that is
slightly worse than the internal consistency of the micrarray data.
A similar result was obtained when conventional RT-qPCR data
from microliter volume samples obtained with cDNA was compared
to the microarray data (Fig. 2C). Reasons for this could include a
combination of systematic differences between measurement
platforms as well as differences in the source tissue or in the cDNA
preparation process. However, the internal noise in the microarray
data is at least as large a contribution as those factors combined. The
microfluidic dynamic array data obtained with PA cDNA has a high
correlation with the microliter RT-qPCR data obtained with cDNA,
with a correlation coefficient r=0.989 (Fig 2D). This is similar to the
result of a comparison between microfluidic dynamic array data for
PA cDNA and microliter RT-qPCR data obtained with PA cDNA
(r=0.989). The reproducibility of the microfluidic dynamic array
data for replicates within a chip and between different chips is very
good (r.0.99) and is shown in Fig. 2E and F. Therefore microfluidic
digital PCR performed on a dynamic array is able to obtain high
throughputgeneexpressiondatathatisessentiallyidenticalinquality
to conventional microliter RT-qPCR and of superior quality to
publicly available microarray data from the same tissue type.
Tissue specificity of gene expression
We measured the expression of both muscle-specific genes and
housekeeping genes. Fig. 3A shows the results from the muscle
specific genes across all tissues, grouped by gene name.
MYH1(MHC IIx/d), MYH2(MHC IIa), MYH6(MYHCA) and
MYH7(MYHCB) are genes that code for isoforms of myosin heavy
chain which together with myosin light chain form the subunits of
myosin. Each molecule of myosin consists of two identical subunits
of myosin heavy chain and two pairs of non-identical subunits of
myosin light chain. Thirteen isoforms of myosin heavy chain have
Figure 1. The 48.48 dynamic array chip. A. Photograph of a 48.48 dynamic array chip showing the position of the sample inlets and the detector
inlets in which the gene expression assay reagents are added. The check valves allow pressure to be applied and released. The accumulators provide
reservoirs to hold the pressure and keep the valves closed during the reaction. The integrated Fluidic Circuit (IFC) is in the center of the chip. This isa
network of fluid lines, NanoFlex
TM valves and reaction chambers. The insert shows a blow-up of a portion of the IFC with one of the 2304 individual
reaction chambers (RC) and the associated containment valves (CV) and interface valve (IV) There are two containment valves and one interface valve
associated with each reaction chamber. B. A computer generated image (heat map) of a 48.48 dynamic array chip obtained after thermal cycling of
the chip. Each of the squares represents 1 reaction chamber from the chip. The color indicates the CT value according to the legend shown on the
right. Black chambers indicate a CT.40.
doi:10.1371/journal.pone.0001662.g001
Microfluidic Dynamic Array
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developmental specificity [13,14]. The expression of these genes
also varies in response to aging, exercise, and disease [15]. MYH1
and MYH2 are expressed primarily in adult skeletal muscle, which
is consistent with the gene expression results observed here. The
products of MYH6 and MYH7 are the predominant forms of
myosin heavy chain expressed in cardiac muscle. MYH7 is also
expressed in skeletal muscle in slow twitch (Type I) muscle fibers,
but the expression of MYH6 shows a high degree of specificity for
cardiac tissue. Our observations are consistent with this: the
expression of MYH6 was more than 100-fold higher in heart than
muscle, and MYH7 was similarly 4–5 fold higher. Interestingly, the
absolute abundance of MYH7 transcripts in heart was higher than
MYH6 (Fig. 3A).
The other five genes in this group are all related to muscle
development and regulation of muscle mass. MYOD1(MYOD)
codes for a myogenic regulatory factor (MRF) and is crucial for the
differentiation of skeletal muscle [16]. The product of MyoD1 is
responsible for the regulation of a wide range of genes during
myogenesis [17–19]. In the work done here expression of this gene
was detected primarily in muscle and fetal muscle which is
consistent with previous reports [20]. However, we also detected
expression at much lower levels in heart, spleen, testis and fetal
testis as shown in Fig. 3A. The proteins encoded by GDF8(MSTN)
and GDF11(BMP11) are both members of the TGF-b superfamily
of transcription factors [21] and are closely related proteins [22].
The product of GDF8 is a negative regulator of skeletal muscle
growth also known as myostatin and is expressed in skeletal
muscle[22]. Mutations in this gene result in increased muscle mass
in mice, cattle, dogs and humans [23,24]. In the work reported
here (Fig. 3A) we detected expression of GDF8 in muscle tissue and
at lower levels in other tissues as well. This result is similar to data
reported for this gene in the GNF SymAtlas[25]. The protein
encoded by GDF11 is a bone morphogenic protein [26]which is
involved in the regulation of anterior/posterior axial patterning in
the developing embryo [27]. The expression of this gene is higher
in many other tissues than in muscle as shown in Fig. 3A and the
GNF SymAtlas [25]. The last two genes in this group, FBXO32
(ATROGIN1 or MAFbx) and TRIM63(MURF1) both code for E3
ubiquitin ligases and their overexpression is associated with muscle
Figure 2. Comparisons of data. The correlation coefficient r is shown above each plot. For details regarding these comparisons see Materials and
Methods. A. Comparison of Duplicate samples from the GeneNote database[10] for 45 genes and two tissues, heart and liver. B. Comparison of data
from the 48.48 dynamic array obtained for preamplifid cDNA (PA cDNA) and data from the GeneNote database for the same genes and tissues. C.
Comparison of the data from the 7900HT Sequence Detection System obtained with cDNA and data from the GeneNote database. D. Comparison of
data from the 7900HT obtained with cDNA and the 48.48 dynamic array obtained with PA cDNA for the same genes and tissues. E. Comparison of the
DDCT values for replicates on one of the 48.48 dynamic array chips used for gene expression analysis for all 44 genes and 18 tissues. F. Pair-wise
comparison of the mean DDCT values from two chips for the same 44 genes and 18 tissues.
doi:10.1371/journal.pone.0001662.g002
Microfluidic Dynamic Array
PLoS ONE | www.plosone.org 3 February 2008 | Volume 3 | Issue 2 | e1662atrophy [28]. The expression of both these genes was found in
muscle. Lower levels of expression of FBXO32 were detected in all
the other tissues, similar to the data reported in GeneNote [12].
The expression of TRIM63 was detected more specifically in
muscle, heart and fetal muscle than in other tissues.
In comparison to the muscle specific genes, the set of
housekeeping genes is expressed across all of the tissues (fig 3B).
Of the genes included here, expression of CSNK2B was the most
stable across all of the tissues as determined by both geNorm [29]
and Normfinder [30] and for this reason was used as the reference
gene for the relative gene expression data. It is interesting to note
that the relative expression levels of pairs of housekeeping genes
are not necessarily constant between tissues. This illustrates one of
the pitfalls of normalizing gene expression results to another gene
– it is extremely challenging, if not impossible, to find genes which
are expressed at constant levels across all tissues. Reliable
quantitative analysis of gene expression levels requires a procedure
to obtain absolute calibration, which can be accomplished either
by creating defined concentrations of synthetic cDNA for each
gene, or less laboriously by performing digital PCR on the original
cDNA sample [6]. Digital PCR involves the isolation and
amplification of single DNA molecules, which is made possible
by the use of the Fluidigm digital array chip [6].
In conclusion, we have shown that the use of microfluidic
dynamic array chips for real-time gene expression analysis is a
rapid and reliable method for high throughput gene expression
analysis. The 48.48 dynamic array chip enables 2,304 individual
reactions to be analyzed with less pipetting than is required to set
up of a conventional 96 well plate. The data has excellent
concordance with conventional real time PCR and has better
reproducibility than DNA microarrays.
Materials and Methods
Instrumentation and microfluidic chips
48.48 dynamic array chips and 12.765 digital array chips were
from Fluidigm Corporation. The NanoFlex
TM 4-IFC Controller
and the BioMark
TM Real-Time PCR System are manufactured
by Fluidigm Corporation. The Nanoflex
TM 4-IFC Controller
utilizes pressure to control the valves in the chips and load samples
and gene expression assay reagents into the reaction chambers.
The BioMark system is a real-time PCR instrument designed to
thermal cycle these microfluidic chips and image the data in real
time. Pre-amplification reactions were done in a GeneAmp PCR
System 9700 from Applied Biosystems. Real-time PCR reactions
in 384 well plates utilized an ABI Prism 7900HT Sequence
Detection instrument from Applied Biosystems.
Real-Time PCR Assays
First strand cDNA samples from 18 different human tissues
were purchased from OriGene, Inc. Universal human cDNA was
purchased from BioChain Institute, Inc. Taq Man Universal
Master Mix, TaqMan PreAmp Master Mix and gene expression
assays were from Applied Biosystems. Prior to use the 20x gene
expression assays were diluted to 10x using the DA Assay Loading
Figure 3. Estimated copy numbers. Using the standard curve shown in Fig. S2 the actual number of copies in the reaction chambers was
estimated from the mean CT values of all the data obtained on the three chips used previously. The data is plotted as the log10. Error bars were
determined from the mean CT values +/2one standard deviation. The raw data for the standard curve in Figure S2 is presented in Table S4.
doi:10.1371/journal.pone.0001662.g003
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samples the TaqMan PreAmp Master Mix was used according to
the manufacturer’s directions except for the amount of the final
dilution [31]. Reactions used either 6.25 mL of cDNA in a 25 mL
reaction or 1.25 mL of cDNA in a 5 mL reaction and were cycled
using the recommended program for 14 cycles. At the end of the
cycling program the reactions were diluted 1:5. Preamplified
cDNA prepared in this way was either utilized immediately or
stored at 220uC until needed. Validation of the preamplification
reaction with the 45 gene expression assays used in this study was
done on the 7900 following the protocol as described by the
manufacturer. Universal cDNA was used for this analysis and one
of the genes, CSNK2B, was used as the reference gene. Only 3 of
the 44 genes expression assays tested gave a value outside of +/
21.5 DDCT. The values obtained with the assays for ACTB and
ENSA were +3.24 and +2.82, respectively. The DDCT value
obtained for the GAPDH assay was 1.52 with the universal cDNA
but was below that value when tested with cDNA from four other
tissues. For the assay for CCND1 expression the DDCT value was
+1.35 but was slightly higher when this analysis was repeated with
other cDNA samples. The mean value obtained for 5 different
cDNA samples was +1.63 DDCT for the CCND1 assay. For real-
time gene expression assays on the dynamic array chips, the
TaqMan Universal Master Mix was modified by the addition of
1/10 volume of DA Sample Loading Reagent (Fluidigm PN
85000735). Preamplified cDNA was added to the modified 2x
TaqMan Universal Master Mix to make the final concentration of
Master Mix 1.1x in the samples. Prior to loading the samples and
assay reagents into the inlets, the chip was primed in the
NanoFlex
TM 4-IFC Controller. Five mL of sample prepared as
described was then loaded into each sample inlet of the dynamic
array chip and 5 mL of 10x gene expression assay mix was loaded
into each detector inlet. The chip was then placed on the
NanoFlex
TM 4-IFC Controller for loading and mixing. After
approximately 55 minutes the chip was ready for thermal cycling
and detection of the reaction products on the BioMark
TM Real-
Time PCR System. The cycling program used consisted of 10min at
95uC followed by 40 cycles of 95uC for 15 sec and 1 min at 60uC.
Data was analyzed using the BioMark Gene Expression Data
Analysis software to obtain Ct values and/or DDCt values. The
number of replicates and the composition of the samples varied
depending on the particular experiment. Details of individual
experiments are given in the Results and Discussion Section.
Reactions for analysis on the 7900HT Sequence Detection System
consisted of 5 mL of TaqMan Universal Master Mix, 1 mLo f1 0 x
Gene Expression Assay Mix and either cDNA or preamplified
cDNA for a final volume of 10 mL per well of a 384 well plate. The
cycling program consisted of a 10 min incubation at 95uC followed
by 40 cycles of 95uC for 15sec and 60ucf o r1m i n .
12.765 Digital array chips
For each sample 13 mL of sample reaction mix was prepared
using 10 mL of TaqMan Universal Master Mix, 1 mL DA Sample
Loading Reagent (Fluidigm PN 85000735) and 2 mL of the
appropriate 10x gene expression assay previously modified by the
addition of DA Assay Loading Reagent (Fluidigm PN 85000735).
Seven mL of cDNA, preamplified cDNA or water was added to the
sample reaction mix. The solution was mixed and 9.5 mL was
added to each of two sample inlets. The chip was then placed on
the NanoFlex
TM IFC Controller and the samples were automat-
ically loaded into the individual reaction chambers. The chip was
then placed on the BioMark System for thermal cycling and
detection of products. Data was analyzed using the BioMark
digital array software and the numbers of positive chambers were
corrected to estimate the true number of copies [32]. This number
was used to determine the number of copies in the original sample.
Determination of relative gene expression
Relative gene expression values were determined using the
2
2DDCT method of Livak and Schmittgen [33]. CSNK2B was used
as the reference gene and muscle was used as the reference sample.
Values for DDCT were obtained directly from the software.
Comparison to Microarray Data and other data
comparisons
The microarray data was obtained from GeneNote [10]. The
data used was MAS5.0 Normalized data. Since all of the data from
the 48.48 dynamic array chips and the 7900 platform was reported
as fold-expression relative to muscle, the data from the microarray
for liver and heart was converted to a similar format using muscle
as the reference. In cases where microarray data from more than
one probe was reported, the data which matched the RT-qPCR
data most closely was used. For comparison to the RT-qPCR data
the mean of the two duplicates was used. All expression data has
been plotted as log2 for comparison to RT-qPCR data. For intra-
and inter-chip comparisons of 48.48 dynamic array data (Fig. 2 E
and F) the DDCT values obtained from the software were used
directly.
Estimated number of copies in preamplified cDNA
samples
Preamplified cDNA for twelve adult tissues was assayed on a
48.48 dynamic array chip with the gene expression assay for
MYH7 and a large number of replicates to determine the CT
values. The number of copies of MYH7 transcript per mL of the
original solution of preamplified cDNA was then determined for
10 of the samples using 12.765 digital array chips. If necessary the
samples were diluted to a concentration suitable for analysis on the
digital array chips. From this data the mean number of copies per
chamber on the 48.48 dynamic array chip was calculated. For
liver and PBL (peripheral blood leukocytes) the expression level for
MYH7 was too low to measure. The CT values determined from
the 48.48 dynamic array chip were plotted against the log10 of the
concentration for samples with a mean copy number per chamber
. than one. The CT for single copy that was determined from the
digital array data was included as the zero value on the plot. This
plot was used as a standard curve to estimate the number of copies
from CT values for the samples used in the gene expression study.
Supporting Information
Figure S1 A. Real-Time PCR curves for a ten-fold dilution
series of preamplified cDNA generated with a gene expression
assay for GAPDH. Each curve represents data from 288 individual
reaction chambers. The curves for each dilution in the series agree
very well except for four curves for the third dilution in the series.
These four curves were localized to four adjacent chambers in on
region of the chip. The most likely explanation is the presence of a
flaw in this particular chip at that position. B. Plot of CT vs log10
of the dilution. Based on this curve the efficiency in this reaction is
89%. Values for the mean CT value and standard deviations of
the curves are shown in Table S2.
Found at: doi:10.1371/journal.pone.0001662.s001 (0.92 MB TIF)
Figure S2 Standard curve constructed from the data in Table S4
and the CT value for single copy determined from the digital array
chip.
Found at: doi:10.1371/journal.pone.0001662.s002 (0.18 MB TIF)
Microfluidic Dynamic Array
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All of the assays that were used for this work are listed in the table.
Assays in Groups 1 and 2 were used for the gene expression
studies. The assays in Group 3 were used for the reproducibility
study reported in Table S3 along with selected assays from Groups
1 and 2. The efficiency of the assays was measured in 48.48
dynamic array chips using preamplified cDNA for human muscle
and with universal cDNA as template. A total of four chips were
used. Error values are based on the standard deviation of 2–4
determinations. Only data that included at least five good data
points was used to calculate the final number. The cDNAs were
purchased from OriGene Technologies (Rockville, MD).
Found at: doi:10.1371/journal.pone.0001662.s003 (0.04 MB
DOC)
Table S2 Mean CT values and standard deviation for curves
shown in Fig. S1. The data in this table shows the relationship
between the relative concentration and CT values for GAPDH.
The standard deviation is signifcantly higher for curve 6 which has
a CT of 25.7. This CT value represents a mean of 8 copies per
chamber as determined by analysis on a 12.765 digital array chip.
Found at: doi:10.1371/journal.pone.0001662.s004 (0.02 MB
DOC)
Table S3 Reproducibility of 48.48 dynamic array data. For this
study the samples were preamplified cDNA from 12 normal, adult
tissues. Four replicates of each sample were loaded into the sample
inlets. Forty-eight gene expression assays were used which
included fifteen assays for genes related to the immune and
inflammatory response(Group3, Table S1) as well as an additional
33 from Groups 1 and 2 in Table S1. The mean of the CT values
obtained for each of for four replicates for each of the 12 tissues
was determined for all 48 assays on each Chip. The data obtained
from each chip was compared in a pairwise fashion to the data
from all of the other chips in a scatterplot. A total of 6 chips were
run. The values determined for the correlation coefficient r and
the slope are shown for all of these comparisons.
Found at: doi:10.1371/journal.pone.0001662.s005 (0.02 MB
DOC)
Table S4 Relationship of CT and number of copies for MYH7.
Forty-seven detector inlets were loaded with the assay for MYH7
and 4 sample inlets were loaded for each sample on a 48.48
dynamic array chip. The samples contained preamplified cDNA
from 12 normal, human tissues. The mean CT value and standard
deviation was determined for the data from all of the positive
chambers. The copies per mL was measured for each of the
samples using the 12.765 digital array chip and the mean copies
per 10 nL chamber was calculated from that value.
Found at: doi:10.1371/journal.pone.0001662.s006 (0.02 MB
DOC)
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